Oracle will integrate Nuance Communications' cloud-based medical speech recognition technology
Focused on improving productivity of clinical programs, reducing costs, and boosting study participant retention, health sciences organizations seek ways to accelerate and streamline clinical trial data collection and management. To support these objectives, Oracle will integrate Nuance Communications' (NASDAQ: NUAN) cloud-based medical speech recognition technology with Oracle Health Sciences e-clinical software.
News Facts
“Nuance’s medical speech and language understanding solutions allow people to stay productive by leveraging mobile devices, and cloud connectivity to communicate anywhere, anytime across devices and platforms,” said Peter Durlach, senior vice president marketing, Nuance Communications. “Embedding Nuance cloud-based medical speech solutions into Oracle’s clinical apps provides a more natural and efficient approach for clinical researchers and staff to deliver accurate information within their workflow.”
· “Clinical trial sponsors and contract research organizations around the world count on Oracle Health Sciences’ leading e-clinical solutions to help them automate and streamline their entire clinical development process,” said Nick Giannasi, vice president, Oracle Health Sciences. “We are committed to continued innovation, and working with Nuance will bring powerful voice-driven capabilities to our e-clinical solutions, making it easier and faster for investigators and study participants to capture and provide accurate clinical trial data.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.